GranitesharesDerivative IncomeBIOY · Nasdaq

GraniteShares YieldBOOST Biotech ETF (BIOY)

Compare Option Income ETFs Compare with others

Price: $20.12; —25 Sept 2026
Assets: $850,000; Total net assets
Expense ratio: 1.07%; Category 0.88%
Yield: —; Trailing distributions

1Y return: —; Category 13.6%
3Y CAGR: —; Category 18.0%
5Y CAGR: —; Category 9.5%

Loading NAV history…

GraniteShares YieldBOOST Biotech ETF

Calendar-year returns

Fund only: no comparison series covers this fund's history.

Risk statistics

Five years of daily closes. Risk-free rate 4% a year.

Standard deviation: —
Maximum drawdown: —
Sharpe ratio: —
Sortino ratio: —
Beta: —
Alpha: —
R²: —
Information ratio: —
Upside capture: —
Downside capture: —
Tracking error: —

Trailing returns compared with benchmark
Period	1M	3M	6M	YTD	1Y	3YCAGR	5YCAGR	10YCAGR	LaunchCAGR
ETF	-0.5%	+1.3%	—	—	—	—	—	—	+2.3%
Derivative Income average	1.6%	6.5%	19.5%	10.3%	13.6%	18.0%	9.5%	8.5%	9.4%
Difference	-2.1%	-5.2%	—	—	—	—	—	—	-7.1%

Holdings

Allocation as last published by the fund.

Credit quality

Share of the bonds by rating.

US government58.6%

Asset mix

Cash89.7%
Bonds11.6%

ETF details

Issuer: Graniteshares
Category: Equity · Derivative Income
Ticker: BIOY
Exchange: Nasdaq
Inception: 4 May 2026 (0.4 years)
Structure: Exchange Traded Fund
Expense ratio: 1.07% (category 0.88%)
Holdings turnover: 0% (category 68%)
Distribution yield: —
Beta, 3 years: 0.00
Total net assets: $850,000

Prices and returns as of 25 Sept 2026; total return with distributions reinvested, before brokerage and taxes. Not investment advice.

Other derivative income ETFs

Other ETFs in the Derivative Income category.

Compare Option Income ETFs